ATF4 and multiple sclerosis: LW-213, a derivative of WGI, was reported to modulate eIF-2α/ATF4/CHOP axis in human cutaneous T-cell (Yu et al., 2021), and given the fact that WGI could pass the blood brain barrier to regulate eIF-2α/ATF4/CHOP in neurons (Chen et al., 2015), it is likely to ameliorate multiple sclerosis via inhibiting caspase-11.